BridgeMD
New treatment option for Acute Myeloid Leukemia
Official title Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
ClinicalTrials.gov ID: NCT03300492
What this study is testing
- What it's testing
- The study examines the application of expanded natural killer cells (NK cells) following haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) for AML or MDS. Haplo-HSCT is a preferred treatment option for patients with AML or MDS without a HLA-matched donor.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient:
- \>18 years of age
- No HLA-matched related or unrelated donor available
- AML or MDS-EB with indication for a haplo-HSCT according to the guidelines of the University Hospital Basel Stem Cell Transplant Team
- Judged by the transplant physicians to have adequate organ function and no contraindications to haplo-HSCT
You likely can't join if
- Patient:
- APL diagnosis
- Presence of relevant (mean fluorescence intensity \>2000) donor-specific anti-HLA antibodies
- Pregnancy
- Necessity of immunosuppression apart from GvHD prophylaxis Exclusion Criteria: Donor:
- Pregnancy
See the full eligibility criteria
- Patient:
- \>18 years of age
- No HLA-matched related or unrelated donor available
- AML or MDS-EB with indication for a haplo-HSCT according to the guidelines of the University Hospital Basel Stem Cell Transplant Team
- Judged by the transplant physicians to have adequate organ function and no contraindications to haplo-HSCT
- Available related haploidentical donor
- Written informed consent Donor:
- \>18 years old, haploidentical parent, sibling or other relative
- Donor suitable for cell donation and apheresis according to standard criteria
- Written informed consent
- Patient:
- APL diagnosis
- Presence of relevant (mean fluorescence intensity \>2000) donor-specific anti-HLA antibodies
- Pregnancy
- Necessity of immunosuppression apart from GvHD prophylaxis Exclusion Criteria: Donor:
- Pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Basel, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Basel, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.